• 대한핵의학회:학술대회논문집
• /
• 대한핵의학회 1977년도 제16차 학술대회
• /
• pp.100.2-100.2
• /
• 1977

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권7호
• /
• pp.4205-4208
• /
• 2013

Objective: The aim of this study was to explore change and significance of serum carcino-embryonic antigen (CEA) before and after gefitinib therapy in patients with advanced non-small-cell lung cancer (NSCLC). Methods: Forty patients with advanced NSCLCs in III~IV stages were selected as study objects given gefitinib therapy combined with routine local radiotherapy until tumor progression or intolerable toxicity. After treatment, all patients were divided into control and non-control groups according to the results of evaluation based on RECIST 1.1 (Response Evaluation Criteria in Solid Tumors in 2009). Peripheral fasting blood from all patients was collected in the early morning and serum CEA was assessed by electro-chemiluminescence immunoassay (ECLIA) before and after treatment. Before treatment, patients were divided into high CEA group (CEA level > 50 ng/mL) and low CEA group (CEA level ${\leq}$ 50 ng/mL). Adverse reactions were noted and progression-free survival (PFS) in both groups was recorded after long-term follow-up that ended in December, 2012. Results: There was no difference between control and non-control groups in CEA level before treatment (P>0.05), whereas serum CEA decreased more markedly lower in the control group after treatment (P<0.01). All patients were divided into high CEA group (26) and low CEA group (14) according to serum CEA level. There was no statistically significant difference between two groups in adverse reactions (P>0.05) but the rate in former group was lower. Additionally, survival rates at 9 and 12 months in high CEA group were clearly higher than in the low CEA group (P<0.01). Conclusions: Serum CEA level can serve as a biochemical index to evaluate the prognosis with gefitinib treatment for NSCLC.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권6호
• /
• pp.3851-3854
• /
• 2013

Objective: To explore changes in the serum tumor makers, hypoxia-inducible factor-$1{\alpha}$ (HIF-$1{\alpha}$) and vascular endothelial growth factor (VEGF) level and their relations in patients with non-small cell lung cancer (NSCLC) before and after intervention. Materials and Methods: Forty patients with NSCLC and 40 healthy individuals undergoing physical examination in our hospital provided the observation and control groups. HIF-$1{\alpha}$ and VEGF levels in serum were detected by enzyme-linked immuno-sorbent assay (ELISA) in the observation group before and after intervention and in control group on the day of physical examination, along with serum carcino-embryonic antigen (CEA), neuron-speci ic enolase (NSE) and squamous cell carcinoma antigen (SCC) levels in the observation group with a fully automatic biochemical analyzer. Clinical effects and improvement of life quality in the observation group were also evaluated. Results: The total effective rate and improvement of life quality after treatment in observation group were 30.0% and 32.5%, respectively. Serum HIF-$1{\alpha}$ and VEGF levels in the control group were lower than that in observation group (p<0.01), but remarkably elevatedafter intervention (p<0.01). In addition, serum CEA, NSE and SCC levels were apparently lowered by treatment (p<0.01). Serum HIF-$1{\alpha}$ demonstrated a positive relation with VEGF level (p<0.01) and was inversely related with CEA, NSE and SCC levels (p<0.01). Conclusions: Significant correlations exist between marked increase of serum HIF-$1{\alpha}$ and VEGF levels and decrease of indexes related to hematological tumor markers in NSCLC patients after intervention.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권9호
• /
• pp.3867-3870
• /
• 2015

Background: To explore whether combined detection of serum tumor markers (CEA, CA72-4, CA19-9 and TSGF) improve the sensitivity and accuracy in the diagnosis of gastric cancer (GC). Materials and Methods: An automatic chemiluminescence immune analyzer with matched kits were used to determine the levels of serum CEA, CA72-4, CA19-9 and TSGF in 45 patients with gastric cancer (GC group), 40 patients with gastric benign diseases (GBD group) hospitalized in the same period and 30 healthy people undergoing a physical examination. The values of those 4 tumor markers in the diagnosis of gastric cancer was analyzed. Results: The levels of serum CEA, CA72-4, CA19-9 and TSGF of the GC group were higher than those of the GBD group and healthy examined people and the differences were significant (P<0.001). The area under receiver operating characteristic (ROC) curves for single detection of CEA, CA72-4, CA19-9 and TSGF in the diagnosis of GC was 0.833, 0.805, 0.810 and 0.839, respectively. The optimal cutoff values for these 4 indices were 2.36 ng/mL, 3.06 U/mL, 5.72 U/mL and 60.7 U/mL, respectively. With combined detection of tumor markers, the diagnostic power of those 4 indices was best, with an area under the ROC curve of 0.913 (95%CI 0.866~0.985), a sensitivity of 88.9% and a diagnostic accuracy of 90.4%. Conclusions: Combined detection of serum CEA, CA72-4, CA19-9 and TSGF increases the sensitivity and accuracy in diagnosis of GC, so it can be regarded as the important means for early diagnosis.

• Journal of Gastric Cancer
• /
• 제11권1호
• /
• pp.46-54
• /
• 2011

Purpose: There are few studies that have focused on the predictors of recurrence after gastrectomy for gastric carcinoma. This study analyzed the patients who died of recurrent gastric carcinoma and we attempted to clarify the clinicopathologic factors that are associated with the timing of recurrence. Materials and Methods: From June 1992 to March 2009, 1,795 patients underwent curative gastric resection at the Department of Surgery, Hanyang University College of Medicine. Among them, 428 patients died and 311 of these patients who died of recurrent gastric carcinoma were enrolled in this study. The clinicopathologic findings were compared between the 72 patients who died within one year after curative gastrectomy (the early recurrence group) and the 92 patients who died 3 years after curative gastrectomy (the late recurrence group). Results: Compared with the late recurrence group, the early recurrence group showed an older age, a more advanced stage, a poorly differentiated type of cancer and a significantly higher tendency to have lymphatic invasion, vascular invasion and perineural invasion.Especially in the gastric cancer patients with a more advanced stage (stage III and IV), the early recurrence group was characterized by a significantly higher preoperative serum carcino embryonic antigen level, perineural invasion and a relatively small number of dissected lymph nodes. Conclusions: The clinicopathologic characteristics of recurrent gastric cancer are significantly different according to the stage of disease, and even in the same stage. For the early detection of recurrence after curative surgery, it is important to recognize the clinicopathological factors that foretell a high risk of recurrence. It is mandatory to make an individualized surveillance schedule according to the clinicopathologic factors.

• Asian Pacific Journal of Cancer Prevention
• /
• 제15권21호
• /
• pp.9367-9373
• /
• 2014

In diagnosis of lung cancer, rapid distinction between small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) tumors is very important. Serum markers, including lactate dehydrogenase (LDH), C-reactive protein (CRP), carcino-embryonic antigen (CEA), neurone specific enolase (NSE) and Cyfra21-1, are reported to reflect lung cancer characteristics. In this study classification of lung tumors was made based on biomarkers (measured in 120 NSCLC and 60 SCLC patients) by setting up optimal biomarker joint models with a powerful computerized tool - gene expression programming (GEP). GEP is a learning algorithm that combines the advantages of genetic programming (GP) and genetic algorithms (GA). It specifically focuses on relationships between variables in sets of data and then builds models to explain these relationships, and has been successfully used in formula finding and function mining. As a basis for defining a GEP environment for SCLC and NSCLC prediction, three explicit predictive models were constructed. CEA and NSE are requentlyused lung cancer markers in clinical trials, CRP, LDH and Cyfra21-1 have significant meaning in lung cancer, basis on CEA and NSE we set up three GEP models-GEP 1(CEA, NSE, Cyfra21-1), GEP2 (CEA, NSE, LDH), GEP3 (CEA, NSE, CRP). The best classification result of GEP gained when CEA, NSE and Cyfra21-1 were combined: 128 of 135 subjects in the training set and 40 of 45 subjects in the test set were classified correctly, the accuracy rate is 94.8% in training set; on collection of samples for testing, the accuracy rate is 88.9%. With GEP2, the accuracy was significantly decreased by 1.5% and 6.6% in training set and test set, in GEP3 was 0.82% and 4.45% respectively. Serum Cyfra21-1 is a useful and sensitive serum biomarker in discriminating between NSCLC and SCLC. GEP modeling is a promising and excellent tool in diagnosis of lung cancer.

• 한국식품영양과학회지
• /
• 제23권2호
• /
• pp.340-347
• /
• 1994

원발성 위암환자로 확진받은 환자들의 암조직과 암조직 주위의 정상점막 조직을 대조군으로 사용하여, $TGF-{\alpha}$와 이에 대한 결합력을 갖고 있는 EGF-Receptor에 대한 mRNA를 면역세포화학적 방법과 in situ hybridization방법을 결합하여 규명하였다. 성장한 세포에서 발견되지 않는 $TGF-{\alpha}$가 위암환자의 조직학적으로는 정상적으로 간주되는 위점막 조직에서 발견된 점으로 미루어 $TGF-{\alpha}$가 암의 분화에 적극적으로 개입하고 있다는 증거가 된다. EMB-11 항체를 사용한 면역세포 화학적 방법에 의해 macrophage를 발견하고, macrophage cell에서 $TGF-{\alpha}$와 EGF-R mRNA가 발현됨을 규명할 수 있었다. 또한 단클론 항체를 이용해 EGF-R에 해당하는 단백질을 발견하였다. CEA를 이용한 면역세포화학 실험에서 정상으로 간주되는 위점막 조직에서 암 세포를 규명하였다. 특히, macrophage cell의 활동이 암의 증식과 더불어 증가하고 있다는 점을 관찰할 수 있었다. 위암과 검사 방법으로서 본 실험에서 사용된 면역세포화학적 기법과 in situ hybridization방법을 사용하여 생검을 통한 조직을 대상으로 성장인자에 대한 검사를 함으로써 정확한 위암의 발생과 진행에 대한 판단을 내리는데 이용할 수 있고 실용성이 있다고 사료된다.

• Tuberculosis and Respiratory Diseases
• /
• 제47권4호
• /
• pp.478-487
• /
• 1999

연구배경 : 전자현미경적 관찰에 의해 진단된 흉막의 악성중피종과 전이성선암 환자를 대상으로 하여 7종의 단일클론항체를 이용한 면역조직화학염색을 시행하고 이들의 발현양상을 비교하여 두 질환을 감별할 수 있는 가장 효과적인 염색방법을 알아보고자 하였다. 방 법 : 면역조직화학염색법은 Fisher사(Fisher scientific)의 1-hour immunohistochemistry방법을 이용하였다. 종양조직은 포르말린으로 고정된 파라핀 조직을 이용하여, $3{\mu}m$ 두께로 잘라서, $85^{\circ}C$에서 가열시킨 후 파라핀을 제거하고, 희석액과 단클론항체를 $45^{\circ}C$에서 15분간 반응시켰다. 각 단계마다 automation buffer로 실온에서 세척하였고, avidin-biotin-peroxidase system을 이용한 immunoperoxidase method로 염색하였다. 조직절편은 $45^{\circ}C$에서 10분간 색소원반응을 시행하였고, 대조염색은 hematoxylin으로 실시하였다. 조직 절편은 최소한 각기 다른 두 구역에서 세포질 또는 세포막이 분명하게 염색될 때 양성으로 판정하였다. 결 과 : 7종의 단일클론항체중 CK, EMA, vimentin, S-100 단백과 Leu-M1은 악성중피종과 전이성선암에서 발현율의 차이는 없었으나, B72-3은 전이성선암에서만 발현되었고, CEA는 전이성선암 전례와 악성중피종 42.9%에서 발현되어서 민감도는 높았으나 특이도는 낮았다. 결 론 : B72-3을 이용한 면역조직화학염색은 악성중피종과 전이성선암의 감별진단에 가장 유용한 방법으로 시사되었으며, 기존에 사용되고 있는 CEA와 B72-3을 함께 이용한다면 악성중피종과 전이성선암에 대한 감별진단력을 높일 수 있을 것으로 사료된다.

• Tuberculosis and Respiratory Diseases
• /
• 제42권6호
• /
• pp.846-854
• /
• 1995

연구배경: Cyfra 21-1은 상피종양세포의 세포질에 존재하는 cytokeratin 19의 분절로서 상피종양세포의 파괴시 혈중내로 유리되므로 그 혈중 농도를 측정하여 종양표지자로 이용할 수 있는 것으로 알려져 있다. 이에 저자들은 폐암, 폐결핵, 기타폐질환 및 정상대조군 환자들의 혈청내 Cyfra 21-1, SCC 항원 및 CEA의 농도를 측정하여 폐암의 종양표지자로서 Cyfra 21-1과 SCC 항원 및 CEA의 진단적 효용성을 비교 관찰하고자 하였다. 또한 편평상피세포암에서 Cyfra 21-1과 평상펴셰포암의 특이 종양표지자로 알려진 SCC 항원과의 진단적 민감도와 특이도의 차이를 비교하고 그 병기 진행에 따른 Cyfra 21-1의 혈중농도의 증가 여부를 관찰하고자 하였다. 방법: 1992년 12월부터 1993년 6월까지 서울중앙병원에 입원하여 조직생검으로 초진단된 원발성 폐암 79예(편평상피세포암 41예, 선암 18예, 기타의 미분화 비소세포양 14예, 소세포암 6예)와 폐결핵 32예, 기타폐질환 23예, 정상대조군 23예를 대상으로 하였다. Cyfra 21-1과 ELSA2-CEA를 사용하였고, SCC 항원은 방사계수측정 kit인 ABBOTT SCC RIABEAD를 사용하였다. 결과: 1) Cyfra 21-1의 혈중농도는폐암군이 평균({\pm}표준편차) $18.38{\pm}3.65\;ng/mL$로서 비교군 $1.16{\pm}0.53\;ng/mL$보다 유의하게 높았다(p<0.0001). SCC 항원은 폐암군에서 $3.53{\pm}6.06\;ng/mL$로서 비교군 $1.19{\pm}0.5\;ng/mL$보다 유의하게 높았다(p<0.01). CEA는 폐암군에서 $35.03{\pm}13.9\;ng/mL$로서 비교군 $2.89{\pm}1.01\;ng/mL$ 보다 유의하게 높았다(p<0.0001). 2) 폐암군내에서는 Cyfra 21-1의 혈중농도가 편평상 피세포암군에서 $31.52{\pm}40.13\;ng/mL$로서 선암군 $2.41{\pm}1.34\;ng/mL$(p<0.0001) 및 소세포암군 $2.15{\pm}2.05\;ng/mL$(p=0.007) 보다 유의하게 높았다. SCC 항원의 혈중농도는 편평상피세포암군에서 $5.1{\pm}7.68\;ng/mL$로서 선암군 $1.36{\pm}0.69\;ng/mL$(p=0.009) 및 소세포암군 $1.1{\pm}0.24\;ng/mL$(p=0.024)보다 유의하게 높았다. 3) 편평상피세포암군에서 폐암의 병기 진행에 따른 Cyfra 21-1의 혈중농도의 증가는 없었다. 4) Cyfra 21-1의 진단양성 기준치를 3.3 ng/mL로 하였을때 편평상피세포암의 민감도가 83%로 선암의 22%, 소세포암의 17%보다 높게 산출되었다. SCC 항원의 민감도가 편평상피세포암에서 39%, 선암에서 11%, 소세포암에서 0% 이었다. CEA의 민감도가 편평상피세포암에서 20%, 선암에서 39%, 소세포암에서 33%이었다. 5) ROC 곡선 분석상 폐암의 진단에서 Cyfra 21-1의 민감도와 특이도가 SCC 항원 및 CEA 보다 우수한 것으로 나타났다. 결론: Cyfra 21-1은 폐임에서 SCC 항원 및 CEA에 비하여 민감도 및 특이도가 높은 종양표지자이며, 특히 편평상피세포암에서 그 민감도와 특이도가 높아 편평상피세포암의 특이 종양표지자로 알려진 SCC 항원보다 우수한 종양표지자로 사료되었다.